Michael Sabranski
Infektionsmedizinisches Centrum Hamburg(DE)
Publications by Year
Research Areas
HIV-related health complications and treatments, HIV/AIDS Research and Interventions, HIV Research and Treatment, Hepatitis C virus research, HIV/AIDS drug development and treatment
Most-Cited Works
- → Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients(2016)276 cited
- → Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease(2011)89 cited
- → Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial(2023)69 cited
- → HIV-Associated Kaposi's Sarcoma(2017)48 cited
- → Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study(2018)47 cited
- → Treatment of AIDS-related lymphomas(2011)32 cited
- → Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV(2021)27 cited
- → Short-Term Neuropsychiatric Tolerability of Bictegravir Combined with Emtricitabine/Tenofovir Alafenamide in Clinical Practice(2019)25 cited
- → Everything fine so far? Physical and mental health in HIV‐infected patients with virological success and long‐term exposure to antiretroviral therapy(2014)22 cited
- → Physical and mental health in HIV-infected patients with virological success and long-term exposure to antiretroviral therapy(2020)16 cited